Akebia Therapeutics (AKBA) Assets Average (2016 - 2025)
Historic Assets Average for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $354.9 million.
- Akebia Therapeutics' Assets Average rose 6608.56% to $354.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $354.9 million, marking a year-over-year increase of 6608.56%. This contributed to the annual value of $231.2 million for FY2024, which is 2264.87% down from last year.
- According to the latest figures from Q3 2025, Akebia Therapeutics' Assets Average is $354.9 million, which was up 6608.56% from $327.9 million recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Assets Average ranged from a high of $636.4 million in Q1 2021 and a low of $213.7 million during Q3 2024
- Its 5-year average for Assets Average is $383.6 million, with a median of $327.9 million in 2025.
- In the last 5 years, Akebia Therapeutics' Assets Average crashed by 5011.2% in 2023 and then skyrocketed by 6608.56% in 2025.
- Akebia Therapeutics' Assets Average (Quarter) stood at $565.8 million in 2021, then dropped by 29.28% to $400.2 million in 2022, then tumbled by 40.44% to $238.4 million in 2023, then decreased by 10.26% to $213.9 million in 2024, then surged by 65.9% to $354.9 million in 2025.
- Its Assets Average was $354.9 million in Q3 2025, compared to $327.9 million in Q2 2025 and $265.4 million in Q1 2025.